Kimer Med
Auckland, New Zealand· Est.
Kimer Med builds modular, host‑targeted biologics to deliver broad‑spectrum antivirals for pandemic‑ready therapeutics.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $14M
AI Company Overview
Kimer Med builds modular, host‑targeted biologics to deliver broad‑spectrum antivirals for pandemic‑ready therapeutics.
Infectious Diseases
Technology Platform
Host‑directed antiviral biologics that target viral dsRNA using modular recombinant fusion proteins for broad‑spectrum activity.
Opportunities
Advancing to Phase 1 trials will unlock licensing and partnership revenue, while the broad‑spectrum platform meets growing demand for pandemic‑ready therapeutics.
Risk Factors
Scientific risk of host‑targeted approach, need for substantial later‑stage funding, and competition from other antiviral platforms.
Competitive Landscape
Few companies focus on host‑directed, dsRNA‑targeting biologics, giving Kimer Med a differentiated niche versus virus‑specific small‑molecule antivirals and vaccine strategies.